Prot# Q3662g: A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled with High-Dose Inhaled Corticosteroids & Long-Acting

Project: Research project

StatusFinished
Effective start/end date7/18/0610/18/10

Funding

  • Quintiles, Inc. (Q3662g)
  • Genentech, Inc. (Q3662g)